Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study
Gastroenterology and Hepatology from Bed to Bench,
8 March 2021
Aim: Although the rate of recurrence of hepatitis B virus after liver transplantation is now very uncommon with both nucleosides and nucleotides analogues represented with lamivudine and Tenofovir disoproxil fumarate respectively, there are few studies comparing the two classes. As there are concerns with resistance with the former and with renal dysfunction in the latter, comparison of the two drugs in long term is of utmost importance in finding the best practice for HBV prophylaxis after LT.
Material and methods:
A total of 302 HBV-related post-transplant patients who received liver transplantation from deceased donors were enrolled in this retrospective study from 2011 to 2015 in Shiraz Organ Transplant Center, Iran. The demographic data, kidney function, recurrence, resistance rate, and acute rejections at 1, 6, 12 months’ interval and after 12 months were compared on TDF (n=209) and Lamivudine (n=93) groups.
During a median follow-up period of 42.9 months, the mean creatinine level was not significantly different between two groups. Hepatitis B virus recurrence rate as well as acute graft rejection episode had no statistical difference in both groups over study period.
Kidney function, creatinine level, disease recurrence and acute graft rejection were comparable between Tenofovir disoproxil fumarate and Lamivudine in patients who received follow up periods.
- Hepatitis B
- liver transplantation
- Abstract Viewed: 0 times